Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment

被引：32
|
作者：
Gilliam, Bruce L. [1 ]
Heredia, Alonso [1 ]
DeVico, Anthony [1 ]
Le, Nhut [1 ]
Bamba, Douty [1 ]
Bryant, Joseph L. [1 ]
Pauza, C. David [1 ]
Redfield, Robert R. [1 ]
机构：
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
来源：
AIDS | 2007年 / 21卷 / 15期
关键词：
D O I：
10.1097/QAD.0b013e3282f02a4f
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
G1 cytostatic drugs reduce CCR5 co-receptor expression and enhance the antiviral activity of a CCR5 antagonist in vitro. The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue. These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection.
引用
收藏
页码：2108 / 2110
页数：3
相关论文
共 50 条
  • [31] Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors
    Chen, Wenwen
    Zhan, Peng
    De Clercq, Erik
    Liu, Xinyong
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (01) : 100 - 112
  • [32] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
    Henrich, Timothy J.
    Lewine, Nicolas R. P.
    Lee, Sun-Hee
    Rao, Suhas S. P.
    Berro, Reem
    Gulick, Roy M.
    Moore, John P.
    Tsibris, Athe M. N.
    Kuritzkes, Daniel R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935
  • [33] Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES
    Nardese, V
    Longhi, R
    Polo, S
    Sironi, F
    Arcelloni, C
    Paroni, R
    DeSantis, C
    Sarmientos, P
    Rizzi, M
    Bolognesi, M
    Pavone, V
    Lusso, P
    NATURE STRUCTURAL BIOLOGY, 2001, 8 (07) : 611 - 615
  • [34] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [35] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
    Seibert, Christoph
    Ying, Weiwen
    Gavrilov, Svetlana
    Tsamis, Fotini
    Kuhmann, Shawn E.
    Palani, Anandan
    Tagat, Jayaram R.
    Clader, John W.
    McCombie, Stuart W.
    Baroudy, Bahige M.
    Smith, Steven O.
    Dragic, Tatjana
    Moore, John P.
    Sakmar, Thomas P.
    VIROLOGY, 2006, 349 (01) : 41 - 54
  • [36] HIV-1 infection in an individual homozygous for the CCR5 deletion allele
    Robyn Biti
    Rosemary Ffrench
    Judy Young
    Bruce Bennetts
    Graeme Stewart
    Tong Liang
    Nature Medicine, 1997, 3 : 252 - 253
  • [37] HIV-1 infection in an individual homozygous for CCR5 Delta 32
    Theodorou, I
    Meyer, L
    Magierowska, M
    Katlama, C
    Rouzioux, C
    LANCET, 1997, 349 (9060): : 1219 - 1220
  • [38] CCR5 structural plasticity shapes HIV-1 phenotypic properties
    Colin, Philippe
    Zhou, Zhicheng
    Staropoli, Isabelle
    Garcia-Perez, Javier
    Gasser, Romain
    Armani-Tourret, Marie
    Benureau, Yann
    Gonzalez, Nuria
    Jin, Jun
    Connell, Bridgette J.
    Raymond, Stephanie
    Delobel, Pierre
    Izopet, Jacques
    Lortat-Jacob, Hugues
    Alcami, Jose
    Arenzana-Seisdedos, Fernando
    Brelot, Anne
    Lagane, Bernard
    PLOS PATHOGENS, 2018, 14 (12)
  • [39] Heterozygous defect in HIV-1 coreceptor CCR5 and chemokine production
    Yang, JY
    Togni, M
    Widmer, U
    CYTOKINE, 1999, 11 (01) : 1 - 7
  • [40] The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1
    Olivieri, Kevin
    Scoggins, Robert M.
    Bor, Yeou-cherng
    Matthews, Aprille
    Mark, David
    Taylor, James R., Jr.
    Chernauskas, David
    Hammarskjold, Marie-Louise
    Rekosh, David
    Camerini, David
    VIROLOGY, 2007, 358 (01) : 23 - 38
12345